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Abstract
Purpose: Early identification of aggressive disease could improve decision support in pancreatic
neuroendocrine tumor (pNET) patients prior to peptide receptor radionuclide therapy (PRRT).
The prognostic value of intratumoral textural features (TF) determined by baseline somatostatin
receptor (SSTR)-positron emission tomography (PET) before PRRT was analyzed.
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Procedures: Thirty-one patients with G1/G2 pNETwere enrolled (G2, n = 23/31). Prior to PRRTwith
[177Lu]DOTATATE (mean, 3.6 cycles), baseline SSTR-PET computed tomography was performed.
By segmentation of 162 (median per patient, 5) metastases, intratumoral TF were computed. The
impact of conventional PET parameters (SUVmean/max), imaging-based TF, and clinical parameters
(Ki67, CgA) for prediction of both progression-free survival (PFS) and overall survival (OS) after
PRRT were evaluated.
Results: Within a median follow-up of 3.7 years, tumor progression was detected in 21 patients
(median, 1.5 years) and 13/31 deceased (median, 1.9 years). In ROC analysis, the TF entropy,
reflecting derangement on a voxel-by-voxel level, demonstrated predictive capability for OS (cutoff =
6.7, AUC= 0.71, p = 0.02). Of note, increasing entropy could predict a longer survival (9 6.7, OS=
2.5 years, 17/31), whereas less voxel-based derangement portended inferior outcome (G 6.7, OS=
1.9 years, 14/31). These findings were supported in a G2 subanalysis (9 6.9, OS = 2.8 years, 9/23
vs. G 6.9, OS= 1.9 years, 14/23). Kaplan–Meier analysis revealed a significant distinction between
high- and low-risk groups using entropy (n = 31, p G 0.05). For those patients below the ROC-derived
threshold, the relative risk of death after PRRT was 2.73 (n = 31, p = 0.04). Ki67 was negatively
associated with PFS (p = 0.002); however, SUVmean/max failed in prognostication (n.s.).
Conclusions: In contrast to conventional PET parameters, assessment of intratumoral heteroge-
neity demonstrated superior prognostic performance in pNET patients undergoing PRRT. This novel
PET-based strategy of outcome prediction prior to PRRTmight be useful for patient risk stratification.
Key words: Pancreatic neuroendocrine tumor, Tumor heterogeneity, [68Ga], [177Lu]-DOTA-
TATE/-DOTATOC, PET/CT, SSTR
Introduction
As an orphan malignancy, the incidence of neuroendocrine
tumors with pancreatic origin (pNET) is continuously rising,
mainly due to technical progress in diagnostic imaging and
improved awareness of treating physicians [1, 2]. Surgical
resection is the only curative approach [3]. In advanced settings,
treatment options include cytotoxic chemotherapy, somatostatin
analogs, or targeted therapies such as tyrosine kinase and mTOR
inhibitors [4–7]. Recently, favorable results have been reported for
unresectable midgut as well as for bronchial NET using peptide
receptor radionuclide therapy (PRRT) with [177Lu]DOTA-D-Phe-
Tyr3-octreotate ([177Lu]DOTATATE) [8, 9].
Tailored medical treatment mainly focuses on proteomics or
gene sequencing; however, their prognostic ability is rather
limited due to small sample sizes, ongoing tumor development,
and incomplete reflection of the entire tumor burden [10, 11].
Recently, the Delphic Consensus Assessment for Gastroenter-
opancreatic (GEP)-NET disease management reported on the
limitations of chromogranin A (CgA) alterations as well as Ki67
in identification of therapy responders. More precise clinical
decision-making increased demand for real-time multidimen-
sional information regarding tumor behavior [12]. Non-invasive
determination of intratumoral heterogeneity as assessed by
baseline somatostatin receptor (SSTR)-positron emission tomog-
raphy (PET) before PRRT has already proven its prognostic
performance by outperforming conventional PET parameters,
such as mean/maximum standardized uptake values (SUVmean/
max) in a mixed cohort of patients scheduled for endoradiotherapy
[13]. However, in particular for pNET, PRRT efficacy prediction
has not been elucidated yet due to considerable heterogeneous
diversity, earlier relapse of pNET patients undergoing radionu-
clide therapy, or mechanisms of tumor escape in dedifferentiated
tumors [14–16]. Decoding a general prognostic phenotype [10],
we hypothesized that intratumoral textural feature (TF) analysis
assessed by a baseline SSTR-PET might address the urgent
clinical need of prognostication in G1/2 pNET patients prior to
PRRT. Patients with potentially poor response to PRRT may be
identified and different therapeutic regimens might be applicable
(e.g., systemic therapies). Therefore, we aimed to elucidate the
prognostic capability of a baseline PET scan in a homogenous
cohort of G1/G2 pNET patients.
Materials and Methods
Since our study comprises a retrospective analysis of routinely
acquired data, the local ethic committees waived the need for
further approval. All patients gave written and informed
consent to the procedures as well as all patients provided
informed consent for scientific analysis of the obtained data.
Patient Population
A total of 31 subjects (14/31 females (45.2 %), mean 60 ±
10 years (y), range, 39–79 y) of four university medical centers
with histologically proven pNET were enrolled. The patients
enrolled in the present subanalysis were part of a larger patient
cohort [13]. The study population was restricted to G1/2 pNET,
as G3 tumors normally suffer from rapid disease progression
under PRRT [17]. Ki67 ranged between 1 and 20 % with a
median of 5 % for the entire cohort (n = 31). Eight out of thirty-
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one (25.8 %) were classified as G1 NET and 23/31 (74.2 %) as
G2NET. InG2NET, themedianKi67was 8% (range, 4–20%).
Analysis of CgA levels before PRRT revealed a range
between 35 and 64.700 μg/l (median, 924 μg/l). Twenty-five
out of thirty-one (80.1 %) patients were pre-treated (somato-
statin analogs, n = 19/31, (61.2 %); surgery, n = 13/31
(41.9 %); chemotherapy, n = 9/31 (29 %); and external beam
radiation, n = 1/31 (3.2 %)). Clinical characteristics of the
patient cohort are given in Table 1.
PRRT was performed with a mean of 7.2 ± 1.0 GBq (194.6 ±
27 mCi; range, 3.3–8.9 GBq, 89.2–240.5 mCi) per cycle using
[177Lu]DOTATATE. In total, the enrolled subjects underwent
112 treatment cycles (median, 4, range, 1–6; mean 3.6 ± 1.2)
aiming at a standard interval of 3 months on a compassionate use
basis [18, 19]. The majority of cases (21/31, 67.7 %) received at
least four subsequent treatment cycles. PRRT was performed
according to The joint IAEA, EANM, and SNMMI practical
guidance on a compassionate use basis or in accordance with the
Rotterdam protocol as published by Kwekkeboom et al., i.e., at
time point of disease progression [18, 19]. Long-acting and short-
acting release formulations were also discontinued according to
[18]. Imaging including both functional (SSTR-PET) and/or
morphologic imaging (CT) modalities was performed every 3–
6 months after PRRT [18, 19].
rogression-free survival (PFS) was defined according to
Response Evaluation Criteria in Solid Tumors 1.1 (RECIST1.1)
by follow-up examinations starting from the time point of baseline
imaging [18, 20]. For the calculation of overall survival (OS), the
time interval between the baseline SSTR-PET examination and
date of death was analyzed.
PET/CT Imaging, Imaging Interpretation
As a prerequisite for treatment initiation, all patients had to
demonstrate sufficient uptake in pre-therapeutic SSTR-PET
computed tomography (CT) [18, 19], i.e., lesional uptake
higher than physiological liver uptake [21]. A mean of 132 ±
35.7 MBq (3.6 ± 0.9 mCi; range, 72–185 MBq, 1.9–5 mCi) of
[68Ga]DOTATATE/-TOC (n = 27, [68Ga]DOTATATE and
n = 4, -[68Ga]DOTATOC) was administered intravenously.
After 60 min, imaging was performed using the following
scanners: Bonn, Biograph 2 PET/CT (Siemens Medical Sol-
utions, Erlangen, Germany); Wuerzburg, Biograph 64 (Siemens
Medical Solutions, Erlangen, Germany); Munich, Gemini TF
PET/CT (Philips Medical, Eindhoven, Netherlands) or Siemens
Biograph 64 (Siemens Medical Solutions, Erlangen, Germany);
Hannover, Biograph 2 (Siemens Medical Solutions, Erlangen,
Table 1. Detailed patient’s characteristics according to Ki67/grading








#1 m 79 Liver, LN Surgery 4 29.7 (802.7) 1 1
#2 f 73 Liver Surgery 3 21.6 (583.8) 1 1
#3 m 71 Liver, bone, LN SSA 4 31.4 (848.6) 2 1
#4 f 65 Liver, bone, LN SSA, CTx 4 29.5 (797.3) 2 1
#5 m 61 Liver, LN SSA 5 32.5 (878.4) 2 1
#6 m 71 Liver None 3 19.9 (537.8) 2 1
#7 m 67 Liver Surgery, SSA, CTx, RTx 2 4.6 (124.3) 2 1
#8 m 62 Liver SSA 4 29.9 (808.1) 2 1
#9 m 57 Liver, LN Surgery, SSA 4 27.9 (754.1) 4 2
#10 m 60 Liver SSA 3 22.5 (608.1) 4 2
#11 m 44 Liver Surgery, SSA 4 32.4 (875.7) 4 2
#12 f 70 Liver None 6 40.6 (1097.3) 5 2
#13 m 52 Liver, bone, LN SSA, CTx 4 29.6 (800) 5 2
#14 m 56 Liver, bone, LN SSA, CTx 4 31.2 (843.2) 5 2
#15 f 70 Liver, LN, lung Surgery 4 26 (702.7) 5 2
#16 f 71 Liver, bone, LN None 4 30.2 (816.2) 5 2
#17 m 63 Liver, bone Surgery 6 44.6 (1205.4) 5 2
#18 f 39 Liver SSA, CTx 1 6 (162.2) 5 2
#19 m 62 Liver, LN Surgery, SSA 4 29.6 (800) 7 2
#20 m 51 Liver SSA 4 30.1 (813.5) 10 2
#21 f 62 Liver, LN Surgery, SSA, CTx 4 27.8 (751.4) 10 2
#22 f 60 Liver None 5 37.3 (1008.1) 10 2
#23 f 50 Liver SSA 3 22.4 (605.4) 10 2
#24 m 53 Liver Surgery 4 29.1 (786.5) 12 2
#25 f 41 LN Surgery, SSA, CTx 2 14.4 (389.2) 15 2
#26 f 53 Liver None 2 15.8 (427) 15 2
#27 m 66 Liver SSA 4 15.9 (429.7) 15 2
#28 m 67 Liver, bone SSA 4 29.7 (802.7) 15 2
#29 f 47 Liver, LN CTx 4 29.6 (800) 20 2
#30 f 68 Liver Surgery, SSA 2 15.2 (410.8) 20 2
#31 f 74 Liver, bone, LN Surgery, CTx 1 8.6 (232.4) 20 2
y years, SSTR-PET somatostatin receptor-positron emission tomography, GBq gigabecquerel, m male, f female, LN lymph node, SSA somatostatin analog, CTx
chemotherapy, RTx radiation therapy, GBq gigabecquerel
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Germany). System spatial resolutions are 4.8 mm for the Gemini
TF, 4.4 mm for the Biograph 64, and 9.3 mm for the Biograph 2
[22–24]. All data was reconstructed using iterative algorithms
implemented by the manufacturer and depending on the routine
protocol of the different medical centers. Scatter and attenuation
correction was performed based on the different transmission
data [13]. To allow for valid pooling of the results between
Siemens and Philips PET/CT scanners, phantom studies based
on the National Electrical Manufacturers Association NU2-2001
standard were conducted in Munich. According to a recent
published study investigating the robustness of TF in GEP-NET
patients using SSTR-PET in a multicentric setting, the following
TF were taken into account [25]: from the gray-level co-
occurrence matrix (Entropy, Homogeneity), from the gray-level
run length matrix (high gray-level run emphasis (HGRE)), and
from the gray-level size zone matrix (intensity variation, high
gray-level zone emphasis (HGZE), zone length non-uniformity
(ZLNU), short-zone high gray-level emphasis (SZHGE), zone
percentage (ZP)). In addition, metabolic tumor volume (MTV)
and total receptor expression (TRE) were assessed. Lesions were
identified by reviewing the SSTR-PET, CT, and fused hybrid
imaging by board-certified nuclear medicine physicians. In case
of multiorgan involvement, a maximum of three lesions per
organ (largest in size and metabolically most active lesion) was
segmented. A manual segmentation method was preferred in
order to exclude adjacent physiological SSTR-avid structures on
PET/CT images [26]. TF analysis was performed by using the
Interview Fusion Workstation (Mediso Medical Imaging Sys-
tems Ltd., Budapest, Hungary) [13]. As previously described, CT
images were available only for localization and not used to guide
delineation of the VOI [27]. Further, conventional PET
parameters (SUVmean/max, metabolic tumor volume (MTV) and
tissue receptor expression (TRE =MTV× SUVmean)) were also
investigated [13]. The radiotracer concentration in the ROIs was
normalized to the injected dose per kilogram of patient’s body
weight to derive the SUVs. For the assessment of TF, 162
volume of interest (median, 5, range, 1–12 per patient) were
manually segmented. In the majority of the cases (22/31, 71 %),
at least four lesions were investigated. Metastases with an MTV
smaller than 10 cm3 were excluded [28].
Statistical Analysis
Statistical analysis was performed using SPSS Statistics 22 and
MedCalc (Vers. 17.4.4). The cutoff values of each parameter for
the prediction of PFS and OS were identified through receiver
operating characteristic (ROC) analysis using the Youden Index
formaximization of specificity and sensitivity [29]. Kaplan–Meier
analysis (univariate analysis) was performed using thresholds
established by ROC analysis in cases in which ROC showed
statistical significant results. A multivariate Cox hazard analysis
was conducted to determine independent prognostic parameters as
well as relative risks (RR) [26, 30]. Non-parametric log-rank tests
were used to assess the differences in the Kaplan–Meier curves;
statistical significance was considered with a p value G 0.05.
Results
Almost all subjects suffered from liver metastases (30/31,
96.8 %), less than half of the cohort demonstrated lymph
node metastases (14/31, 45.2 %), 8/31 suffered from bone
lesions (25.8 %), and 1/31 (3.2 %) showed pulmonary
metastases (Table 1).
During an observation period/follow-up of median
3.7 years, disease progression occurred in 21/31 subjects
(67.7 %) after a median of 1.5 y from the baseline PET scan
(range, 0.8 months–4.5 y). Thirteen out of thirty-one
(41.9 %) patients died from their tumor after a median of
1.9 y (range, 0.8 months–4.6 y). Of those, 11/13 (84.6 %)
belonged to the G2 group (mean Ki67, 11 %). The median
proliferation index Ki67 in the deceased patients was 5 %
(range, 2–20 %).
Entire Cohort
In ROC analysis of TF, entropy demonstrated a significant
predictive ability for OS (cutoff = 6.7, AUC = 0.71, p = 0.02)
with an accuracy of 71 %. Increasing entropy could predict
longer survival (9 6.7, OS = 2.5 y, 17/31), whereas less
entropy portended inferior outcome (G 6.7, OS = 1.9 y, 14/
31, Table 2, Supplementary Table a: see electronic supple-
mentary material (ESM)). All the investigated conventional
PET parameters (SUVmean/max, MTV, TRE) failed in
response prediction (Supplementary Table b).
Subsequent Kaplan–Meier analysis revealed a significant
distinction between high- and low-risk patients for OS using
entropy (p = 0.045) in the whole cohort (PFS, n.s.).
In Cox hazard analysis, entropy and intensity variation
demonstrated significance for OS (p G 0.05, respectively).
For PFS, none of the investigated conventional PET
parameters (SUVmean/max) or other TF were significant.
Regarding clinical parameters, the cumulative administered
dose reached significance for OS (p = 0.04, r = 0.37) and
Ki67 for PFS prediction (p = 0.002, r = − 0.54). For those
patients below the ROC-derived threshold for entropy, the
RR of cancer-related death after PRRT was 2.73 (n = 31, CI
1.07–7.01; p = 0.04) (Fig. 1, Supplementary Table c in
ESM).
Neither Ki67 nor grading demonstrated significant corre-
lation with the independent heterogeneity parameters (e.g.,
entropy/Ki67, r = − 0.27, n.s.).
Subanalysis of G2 NET
In ROC analysis of G2 NET, entropy reached significance
for OS prediction with an accuracy of 70 % (ROC, cutoff =
6.9, AUC = 0.72, p = 0.03). Regarding OS prediction, the
findings of the entire cohort were supported in a subanalysis
of G2 NET (9 6.9, OS = 2.8 y, 9/23 vs. G 6.9, OS = 1.9 y, 14/
23, Table 2).
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In Kaplan–Meier analysis, no statistical significance was
reached in the G2 subgroup (p = 0.072). Results are
displayed for the entire cohort and the G2 group (Table 3);
respective Kaplan–Meier plots for OS are given in Fig. 2.
In Cox analysis, entropy reached significance (p = 0.03) for
OS prediction. In accordance with the findings for the entire
cohort, the RR of cancer-related death after PRRTwas 2.89 (CI
0.8–10.44; p = 0.1) for the G2 subgroup (Fig. 1, Supplementary
Table c in ESM). The parameter intensity variation [13]
trended to be significant in Cox analysis (p = 0.05).
For both the entire cohort as well as the G2 subgroup,
results for ROC and Cox analyses of investigated parameters
are presented in Supplementary Table b in ESM.
Discussion
This is the first study to assess intratumoral heterogeneity as
a risk stratification tool for pNET patients scheduled for
PRRT. Entropy, reflecting derangement on a voxel-by-voxel
level, outperformed standard conventional PET parameters
in prognostication. These findings were further corroborated
in a G2 subanalysis. However, this group per se includes a
wide range of NET from 2 to 20 %, i.e., that the therapeutic
response of a Blow^ G2 NET scheduled for PRRT might
differ from a G2 NET with an increased Ki67 [16].
Biopsy carries the potential for tumor under-sampling,
and as a consequence, inaccurate therapeutic decisions can
be made [31]. Hence, as a non-invasive whole-body
molecular tool considering the extent of disease, PET-
based assessment of intratumoral heterogeneity might serve
as a novel diagnostic biomarker reflecting the entire
phenotypical tumor burden. As previously described, the
prognostic value of TF derived by PET has been success-
fully investigated in different tumor types [26, 32–34]. In
our previous trial investigating various disease entities, TF
analysis of a baseline SSTR-PET/CT proved prognostic
value in PRRT candidates [13]. In the present study, we
focused on subjects only suffering from NET of pancreatic
origin. For NET, treatment options have improved in the last
years [35]: The NETTER-1 trial revealed impressive find-
ings using PRRT in midgut NET [8]. Moreover, recent
developments of systemic agents such as everolimus or
axitinib have also demonstrated favorable results. However,
attention should also be paid to cardiac adverse events
Table 2. Receiver operating characteristic (ROC) analysis for progression-free (PFS) and overall survival (OS) for the textural feature entropy (independent
according to Cox analysis)
p value Cutoff value Sensitivity (%) Specificity (%) Accuracy (%) PPV (%) NPV (%) AUC ≤ cutoff 9 cutoff
Entropy—entire cohort (n = 31)
PFS 0.4 6.7 50 63.6 54.8 71.4 41.2 0.47 1.3 years (14/31) 1.9 years (17/31)
OS 0.02* 6.7 69.2 72.2 71 64.3 76.5 0.71 1.9 years (14/31) 2.5 years (17/31)
Entropy—G2 NET (n = 23)
PFS 0.14 6.9 58.8 33.3 52.2 71.4 22.2 0.66 1.3 years (14/23) 1.8 years (9/23)
OS 0.03* 6.9 81.8 58.3 70 64.3 77.8 0.72 1.9 years (14/23) 2.8 years (9/23)
Given for entire cohort (n = 31) and the G2 neuroendocrine tumors (NET, n = 23) subgroup. PFS and OS below the cutoff (≤ cut-off) and above to the cutoff
(9 cutoff) with the number of patients for each group is shown in brackets. With increasing entropy, PFS and OS increase
PPV positive predictive value, NPV negative predictive value, AUC area under the curve
*Statistically significant
Fig. 1. Relative risk (RR) charts with 95 % confidence interval (CI) using the ROC-derived threshold (Table 2) of entropy for
overall survival. a Entire cohort (n = 31) and b G2 neuroendocrine tumor subgroup (n = 23). When the RR is exactly 1, the risk is
unchanged. For those patients below the ROC-derived threshold of entropy, the RR of cancer-related death after PRRT
increases (indicating worse outcome, applies to both the entire cohort and the G2 subcohort). Asterisk denotes statistically
significant.
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(grade 3/4 hypertension) leading to axitinib withdrawal in
20 % of patients [6, 36]. Hence, novel risk stratification
approaches for this tumor entity might be intensively sought
for: As demonstrated in this study, imaging-based survival
prediction using TF analysis might be helpful to differentiate
between low-risk and high-risk groups. Of note, entropy
reached significance in all three statistical tests (ROC,
Kaplan–Meier, Cox analysis) emphasizing its potential in
response prediction independent of other investigated vari-
ables at least for the entire cohort. However, clinical
implications have to be made with extreme caution, as the
herein presented findings should rather be interpreted as a
Bproof-of-concept^ and further research in larger, more
homogeneous cohorts is definitely warranted.
Analyzing pre-therapeutic [68Ga]DOTATOC scans of
liver metastases in pNET patients scheduled for [Y-90/Lu-
177] treatment, a SUVmax threshold of 9 16.4 for achieving
radiologic response was proposed [37]. In our study, a
cohort treated with the less nephrotoxic and more common
Lu-177 was enrolled [38]. However, comparative thresholds
were reached, but the SUV was not significant in our
analysis. Similar to our findings, Gabriel also reported that
the SUV profile of a baseline [68Ga]DOTATOC PET does
not add additional information for response prediction in
PRRT patients [39]. Sansovini et al. have recently proven
that a negative 2-deoxy-2-[18F]fluoro-D-glucose (FDG) PET
scan in advanced pNET patients treated with [177Lu]DOTA-
TATE was linked to a better outcome after PRRT; however,
[18F]FDG PET is not routinely assessed in treatment
planning [40].
Higher entropy values are related to superior outcome in
our study. A multivariate Cox analysis corroborated these
findings: the RR for cancer-related death for those patients
below the ROC-derived threshold of entropy indicated an
almost threefold increased mortality compared to that for the
low-risk group (Fig. 1). These results are contrary to
findings in [18F]FDG PET studies investigating TF in
pancreatic ductal carcinoma or non-small cell lung cancer
(low entropy associated with longer OS) [41, 42]. Under-
standably, results from [18F]FDG PET in highly metaboli-
cally active tumors cannot be directly transferred to SSTR-
PET; however, these findings emphasize the value of tumor
heterogeneity assessment.
The value of entropy in patients with esophageal cancer
undergoing RTx has been recently evaluated. Although
responders were associated with greater local heterogeneity
than non-responders, responders presented lower entropy
values [33]. The response of NET tumor tissue to radiation
exposure, however, might vary [43], and the included
patients in the present study were heavily pre-treated with
CTx and RTx (30 %), which could also have a certain
impact on the SSTR fluctuations on the tumor cell surface.
Table 3. Results of Kaplan–Meier analysis for overall survival (OS) for the entire cohort (n = 31) and G2 neuroendocrine tumors (NET, n = 23) for the
textural feature entropy. Asterisk denotes statistically significant
ξ2 p value HR negative CI HR positive CI
Entire cohort (n = 31) 4.03 0.045* 0.32 0.11–0.97 3.12 1.04–9.38
G2 NET (n = 23) 3.24 0.072 0.27 0.08–0.89 3.60 1.13–12.10
CI confidence interval, HR hazard ratio
Fig. 2. Kaplan–Meier plots and number-at-risk tables for the probability of overall survival. a Entire cohort, n = 31, and b G2
neuroendocrine tumor subgroup, n = 23. Low-risk group (solid lines) was identified by various textural parameters measured on
somatostatin receptor-positron emission tomography/computed tomography (SSTR-PET/CT) before peptide receptor
radionuclide therapy. Cutoff values derived by receiver operating characteristics (ROC) analysis were used (Table 2). Only
entropy was significant in both ROC and Cox analysis; d days.
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Moreover, as intratumoral phenotypic heterogeneity is
frequently observed in NET even between synchronous or
metachronous metastases, no attempt was performed to
correlate these histopathological findings with patient out-
come [15]. Wetz et al. have recently reported on the
predictive role of asphericity in GEP-NET patients sched-
uled for PRRT: a higher level of asphericity was associated
with poorer outcome. However, compared to the present
study investigating SSTR-PET, heterogeneity parameters
were derived from [111In-DTPA0]octreotide scintigraphy
[44], which has a lower affinity to SSTR2A compared to
its PET counterparts [45]. Moreover, entropy and asphericity
differ in their equations, which also serves as a possible
explanation for the different results: The latter one quanti-
tates the deviation from spherical of the shape of the MTV,
and it takes both the mean surface S and the mean volume V
into account [44, 46]. On the contrary, entropy considers I as
the voxel value in the ROI and P(I) as the probability of the
occurrence of that pixel value [47]. Apart from that, in the
present study, SSTR-PET had been used, while Wetz and
co-workers performed a SPECT approach [44]. Taken
together, the exact association between the herein presented
imaging-derived analysis of tumor lesion texture and the
underlying tumor biology must be further determined in
prospective, longitudinal studies.
In contrast to previous findings, hepatic tumor burden did
not turn out as an independent survival predictor, mainly
since almost the entire cohort of our patients (97 %) suffered
from liver metastases [48]. Of note, Ki67 did not correlate
significantly with the investigated heterogeneity parameters
emphasizing their independence. Correlating the prolifera-
tion index with outcome variables, Ki67 demonstrated its
potential in PFS prediction but failed for OS. This might be
also caused by sampling variability, as needle biopsies are
typically not guided to regions with a higher proliferative
rate [15].
This multicenter analysis has several limitations. First,
only a limited number of patients could be included in
this study, even though pNETs have a low annual
incidence [2]. Additionally, imaging protocols differ
slightly from center to center, including various PET
reconstruction algorithms and different used PET scan-
ners. Moreover, no harmonization between the used
Biograph 2 and 64 PET has been performed. Compared
to previous investigations [37], this might explain why the
SUVmax did not turn out as a significant predictive
parameter and other conventional PET parameters, like
SUVpeak, could be subject of future studies. The herein
stated OS for pNET patients under PRRT is significantly
lower as described previously [16, 49]: However, it
remains a matter of debate if the OS should be defined
from diagnosis and treatment initiation or from baseline
SSTR-PET. Moreover, therapeutic algorithms might also
vary between centers, as the treating nuclear medicine
physician has to adjust treatment planning under current
circumstances (e.g., due to renal impairment); nonetheless,
this reflects a typical clinical situation. Furthermore, in
our cohort, the number of treatment cycles ranged from 1
to 6; however, the majority of the cases (70 %) received
at least four radiopeptide administrations (median
4 cycles). Changes of imaging-derived parameters be-
tween subsequent scans might be also of prognostic value;
however, functional follow-up imaging was not available
in every patient. Moreover, in only 70 % of the cases, at
least four lesions could be manually segmented and
metastases with MTV smaller than 10 cm3 were not
considered. Ki67 is prone to sampling bias as well as
particular inaccuracy regarding the time lag of assessment
and subsequent SSTR-PET scan. Due to the different
affinities to SSTR2A, the use of [68Ga]DOTATATE/-TOC
might have also led to a certain data bias [45]. In
accordance with the reported robustness of certain TF
published in [25], a pre-selection of heterogeneity param-
eters has been performed in the present study. Hence, a
limited number of TF had been investigated, and
therefore, no correction for p values was applied to adjust
for multiple tests, but such procedures could be subject of
future studies [50]. Consequently, as a Bonferroni correc-
tion had not been applied, the herein derived findings
must be interpreted with caution. Moreover, a more
homogenous study setting might strengthen our prelimi-
nary findings, in particular by enrolling a larger, prospec-
tive cohort using the same scanners and without variances
in the imaging protocol.
Conclusion
As demonstrated in this multicenter study, application of
entropy as obtained by baseline SSTR-PET might be useful
for differentiating high-risk from low-risk groups in pNET
patients scheduled for PRRT.
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